In The News
We’ve announced the latest additions to its free webinar series, with two webinars taking place in March and April 2017 to commemorate Multiple Sclerosis (MS) and Parkinson’s awareness months.
Miroslav Backonja, M.D., Senior Medical Director at Worldwide Clinical Trials (www.worldwide.com), will be presenting two sessions at the American Academy of Pain Medicine (AAPM) Annual Meeting, being held March 16-18, 2017 in Orlando, Florida.
Worldwide Clinical Trials has been recognized for excellence in clinical research by Life Science Leader’s 2017 CRO Leadership Awards. Worldwide came away a winner in 12 of the 15 potential categories in the annual awards program, which is based on a survey of biopharmaceutical company executives who have decision-making influence and authority when it comes to working with clinical research organizations (CROs).
Worldwide Clinical Trials (www.worldwide.com) and Bellerophon Therapeutics (www.bellerophon.com) have been selected as finalists in the 2017 Clinical Research & Excellence (CARE) Awards in the “Clinical Partnership of the Year” category. This category recognizes collaborations between organizations whose clinical trial activity has set a new benchmark in partnering activity.
MORRISVILLE, NC, FEBRUARY 28, 2017 – Two scientists have joined the new Michael F. Murphy Clinical Research Methodology Fellowship Program at Worldwide Clinical Trials (www.worldwide.com), demonstrating the company’s commitment to not only delivering unmatched scientific expertise to its current clients, but also its dedication to preparing scientists who will support the increasingly complex clinical trials of tomorrow.
More than 80 candidates applied for the sought-after fellowship roles, which offer hands-on clinical research experience working alongside some of the top medical and scientific experts in the industry.
George Atiee, M.D., Medical Director and Principal Investigator at Worldwide Clinical Trials Early Phase Services, will present at the annual Outsourcing in Clinical Trials West Coast (OCT-WC) conference, being held February 22-23, 2017, in Burlingame, Calif. Dr. Atiee, who has 20 years of experience in both early and late phase drug development, will present his recommendations and best practices for principal investigators in ensuring successful study conduct on Wednesday, February 22 at 4:40 p.m. PT.
Worldwide Clinical Trials has announced the latest additions to its free webinar series, both taking place in February. The first of two informative sessions will address the future of heart failure research in honor of Heart Month, while the second will examine the impact of emerging opportunities on innovative trial design and execution in rare disease clinical trials on Rare Disease Day.
Worldwide Clinical Trials has been ranked as the industry’s #1 provider of Overall Contract Research, which includes non-clinical research services, in the “2017 Nice Insight Preclinical and Clinical Contract Research Survey.”
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has selected Worldwide Clinical Trials (“Worldwide”) as its Clinical Research Organization (CRO) for the AURORA Phase 3 study of volcosporin for the treatment of active lupus nephritis (LN).
Margo Holland has been named as the Vice President of Global Quality at Worldwide Clinical Trials (www.worldwide.com). This appointment demonstrates Worldwide’s commitment to ensuring high standards of quality are met on behalf of its customers around the world.
Worldwide Clinical Trials (www.worldwide.com) has been named “Best in Neuroscience Therapeutics” in the 2016 Corporate LiveWire Healthcare and Life Science Awards.
Barbara Zupancic, Director of Global Patient Recruitment and Retention at Worldwide Clinical Trials, will present at this year’s Summit for Clinical Operations Executives (SCOPE), being held Jan. 24-26 at the Hyatt Regency in Miami, FL.
The CRO will support a Phase 3 trial in patients with heart failure and reduced ejection fraction, commencing in H2 2017 across 60 medical centers in the United States
SAN DIEGO, Calif., January 5, 2017 — Renova™ Therapeutics, a biotechnology company developing gene therapy treatments for congestive heart failure and type 2 diabetes, announced today that it has selected Worldwide Clinical Trials as its Clinical Research Organization (CRO) for a Phase 3 study of RT-100 AC6 gene transfer for the treatment of patients with reduced ejection fraction heart failure.
Worldwide Clinical Trials (www.worldwide.com) will present a webinar, titled “Necessity is the Mother of Invention: The Impetus for Observational Research in Orphan Drug Development,” on Wednesday, December. 7, 2016 at 11 a.m. ET. Worldwide’s Chief Medical and Scientific Officer, Michael Murphy, M.D., Ph.D., will lead the discussion on emerging trends in clinical trial methodology for orphan disease drug development.
To mark Alzheimer’s Disease Awareness Month in November, Worldwide Clinical Trials (www.worldwide.com) will host a webinar, titled “Alzheimer’s Disease Clinical Trials: Improving Screen Failure and Recruitment Rates,” on Thursday, Nov. 10, 2016 at 11 a.m. E.T.
Worldwide Clinical Trials has announced findings from a recent global survey that evaluated preferences of investigators who participate in central nervous system (CNS) studies that employ rater training and surveillance methodologies.
Lorna Graham, Associate Director of Project Management for Worldwide Clinical Trials (www.worldwide.com), will present at Evidence USA 2016, which is being held at the Hilton Philadelphia City Avenue in Philadelphia, PA, Oct. 18-19, 2016. Graham’s session is titled: “Is Technology the Key to Naturalistic Observational Research?”
Worldwide Clinical Trials (www.worldwide.com), will present a webinar, titled “Accelerating Analgesics Therapeutic Development by Optimizing Early Human Experimental Models of Pain,” on Thursday, Oct. 27, 2016 at 11 a.m. E.T.
Worldwide Clinical Trials (www.worldwide.com), one of the world’s leading, full-service contract research organizations (CROs), has been announced as a finalist in the prestigious 2016 Scrip Awards. Selected in the “Best Contract Research Organization – Full Service Providers” category, Worldwide was chosen by a distinguished panel of life science industry experts, and is included as a finalist among six leading, global CROs.
Worldwide Clinical Trials (www.worldwide.com) has announced that Jeffrey Zucker, the company’s vice president of Feasibility and Recruitment Optimization, will present at this year’s MAGI’s Clinical Research Conference, taking place Oct. 23 to 26 at the Planet Hollywood Resort in Las Vegas, Nev.
Sep 22, 2016 WARSAW, POLAND – Worldwide Clinical Trials (www.worldwide.com), one of the world’s leading, full-service contract research organizations (CROs), has opened a new office in the heart of Warsaw’s central business district.
To commemorate World Heart Day, Worldwide Clinical Trials will present a free webinar, titled “Piloting the Queen Mary: The Unique Challenges of Cardiovascular Outcome Studies,” on Thursday, September 29, 2016 at 11 a.m.
Worldwide Clinical Trials has appointed Miroslav Backonja, M.D., as Senior Medical Director of Neuroscience, Medical and Scientific Affairs. Dr. Backonja, who brings more than two decades of experience to his new role, will serve as Worldwide’s global lead for its analgesia franchise.
Worldwide Clinical Trials will host a free webinar on Thursday, Aug, 18 at 11 a.m. ET, titled “Improving Clinical Site Performance: It’s All About Relationships,” that explores the impact of relationships between sponsors, CROs and sites on clinical trial planning and execution.
A recent survey by Worldwide Clinical Trials reveals that 62 percent of respondents are more likely to engage a clinical research organization (CRO) partner for clinical research than they were five years ago, demonstrating the increasingly vital role that CROs are playing in modern drug development, and the importance of partnering with a CRO that offers medical and scientific expertise. Conducted at DIA 2016, held June 26-30, 2016, in Philadelphia, Pa., the survey gauged the opinions of nearly 300 drug development leaders and executives from pharmaceutical and biotechnology companies who visited the Worldwide booth during the DIA meeting.
Worldwide Clinical Trials will host a free webinar, titled “Are We Moving Toward ‘Siteless’ Clinical Trials? Exploring the Current and Future Potential of Home-Based Studies,” on Thursday, July 14, 2016 at 11 am ET. Leading the discussion will be Worldwide’s Chief Medical and Scientific Officer, Michael Murphy, M.D., Ph.D.
MORRISVILLE, NC, May 16, 2016 – Jeanine Ronniger, director of project management at Worldwide Clinical Trials, will present at the 6th Annual Outsourcing in Clinical Trials Europe (OCT-EU) conference, being held May 17 and 18 in Paris, France. Ronniger, who has more than 16 years of experience in clinical trials project management, will present to industry peers on how sponsors and CROs can work together to share risk, strengthen their bond and improve study success on Wednesday, May 18 at 11:30 a.m.
Worldwide Clinical Trials has opened a new, larger depot site in St. Petersburg, Russia. The spacious, new facility – at 1,300 square meters in size – allows for the storage and distribution of a wide range of clinical trial materials with special requirements and conditions for storage, as well as distribution. The new location is one of several Worldwide Clinical Trials depots located in Russia, Georgia and Ukraine.
To mark Parkinson’s Awareness Month, Worldwide Clinical Trials will host a webinar, titled “Challenges of Clinical Research in Parkinson’s Disease,” on Wednesday, April 27, 2016 at 11 a.m. ET. Presenting the webinar will be Tom Babic, M.D., Ph.D., vice president of Neuroscience for Worldwide Clinical Trials, who will explore the unique challenges of clinical research in Parkinson’s disease, and the opportunities that exist to optimize clinical trial outcomes.
Worldwide Clinical Trials has been recognized for excellence in clinical research by Life Science Leader’s 2016 CRO Leadership Awards. The annual awards are based on a survey of more than 2,200 biopharmaceutical company executives, who are responsible for influencing decisions to collaborate with CROs on clinical research programs.
Worldwide Clinical Trials announces that Michael Murphy M.D., Ph.D., the company’s Chief Medical & Scientific Officer, will lead a roundtable discussion entitled, “Retention and Faster Access to Rare Disease Patients,” during the World Orphan Drug Congress (WODC) 2016, set for April 20-22 in Washington D.C.
Worldwide Clinical Trials announces the findings from a unique, multinational survey that evaluated the experiences of clinical trial site investigators who use electronic clinical outcome assessment (eCOA) technologies. The company will present its findings at the Symposium on Advances in Alzheimer Therapy (AAT) meeting, which is being held in Athens, Greece, March 9-12, 2016.
Worldwide Clinical Trials recently opened a new office at Waterfront House on the Beeston Business Park in Nottingham, with company leaders welcoming approximately 185 employees to the space in January. The new site features plentiful light, bright colours, and collaborative work and meeting spaces.
Rare Disease Day, set for February 29, is intended to raise awareness around the world about rare diseases and their impact on patient lives. Worldwide Clinical Trials will mark the day with a free webcast that demonstrates new perspectives on the study of rare diseases, highlighting the need for the industry to rethink its approach to clinical trial design and execution within this complex area of medicine.
Jeffrey Zucker, vice president of Feasibility and Recruitment Optimization at Worldwide Clinical Trials, will present at this year’s Summit for Clinical Operations Executives (SCOPE), being held Feb. 23-25 at the Hyatt Regency in Miami, FL. Zucker will discuss how sponsors can rebuild and enhance site partnerships to optimize study execution, supporting SCOPE’s ”Improving Site Study Activation and Performance” portion of the conference. His presentation will take place on Thursday, Feb. 25 at 11:05 a.m.
A Worldwide Clinical Trials expert will present at Evidence EU 2016, which will be held at Victoria Park Plaza in London, 24-25 February 2016. Worldwide will host an informative seminar on technology and future advances for late phase research on Wednesday, 24 Feb at 15:00. The seminar, led by Lorna Graham, associate director of project management at Worldwide, will focus on how to leverage technology to keep up with new regulations and standards in late phase research.
Worldwide Clinical Trials has been recognized as a leader in Quality, Productivity and Innovation by the 2015 CRO Leadership Awards, sponsored by Life Science Leader.
Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the “Company”) has selected Worldwide Clinical Trials (WCT) to commence the pre-patient enrollment activities for the conduct of a Phase 2b trial of the Company’s compound bryostatin-1 for the treatment of Alzheimer’s disease. WCT is a leading global clinical research organization with substantial experience in conducting trials in Alzheimer’s disease.
TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer’s disease into the second of its two Phase III clinical trials of LMTX™, a tau aggregation inhibitor, for the treatment of Alzheimer’s disease. This multi-centre, placebo-controlled clinical trial (Protocol TRx-237-005) is aimed at assessing the efficacy of LMTX™ in people diagnosed with mild Alzheimer’s disease. The study is also evaluating the safety and pharmacokinetic profile of LMTX™, and incorporates imaging endpoints in all subjects.
Worldwide Clinical Trials has been recognized as a leader in Quality, Productivity and Regulatory performance by the 2014 CRO Leadership Awards, sponsored by Life Science Leader.
BioClinica®, Inc., a global provider of technology-enhanced clinical trial management solutions, today announced that Worldwide Clinical Trials, Inc. has selected BioClinica’s OnPoint CTMS (clinical trial management system) to support international studies spanning all phases of drug development in diverse therapeutic areas. By implementing BioClinica’s web-based OnPoint CTMS the global, full-service contract research organization (CRO) anticipates improved efficiencies in data flow and workflow with cost-savings in time, labor, and operational expenses.
Worldwide Clinical Trials Inc, today acknowledged receipt of strong ratings and recommendations from one of the industry’s leading independent market research firms, Industry Standard Research (ISR). In ISR’s recently published, ‘2012 CRO Quality Benchmarking Report’, CROs (Clinical Research Organisations) were quantitatively assessed for delivery strengths and weaknesses. Sponsors’ selection drivers, outsourcing volume, and provider preferences were also measured.
See what Worldwide Clinical Trials can do for you.
Fill out the brief form below to get in touch.
Your form has been successfully submitted! Thank you for your interest in Worldwide Clinical Trials. We will respond to your inquiry as soon as possible.